Physician profile
April E Barnes
NPI 1194163832
$52,450.08
in general payments reported to CMS, 2019-2025
11 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.03 · 2020: $63.41 · 2021: $81.73 · 2022: $29.17 · 2023: $73.97 · 2024: $29K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $20K · Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,971.23 |
| Travel and Lodging | $19,819.43 |
| Food and Beverage | $472.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $52,056.47 | 2020-2025 | Bexsero, Pediarix, Menveo |
| Pfizer INC. | $202.89 | 2020-2025 | |
| Sanofi Pasteur INC. | $43.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $34.63 | 2021-2024 | Flumist Quadrivalent |
| Merck Sharp & Dohme LLC | $30.24 | 2022-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Cranial Technologies, INC | $15.66 | 2022 | |
| Aytu Biopharma, INC. | $15.06 | 2024 | Karbinal |
| Cipher Pharmaceuticals US LLC | $14.44 | 2025 | Natroba, Spinosad |
| Ironshore Pharmaceuticals INC. | $13.03 | 2019 | |
| Corium, LLC | $12.66 | 2023 | Azstarys |
| Tris Pharma INC | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.